AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
edrophonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quaternary ammonium compounds | 988 | 312-48-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.80 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 55 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK4,DDR1,EPHB4,GRK2,MAPK7,PDK4,SIK2,STK33,TEK | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 3, 1951 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V04CX07 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Other diagnostic agents |
| FDA MoA | N0000000177 | Cholinesterase Inhibitors |
| MeSH PA | D000931 | Antidotes |
| MeSH PA | D002800 | Cholinesterase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:33295 | diagnostic agent |
| CHEBI has role | CHEBI:37733 | EC 3.1.1.8 (cholinesterase) inhibitor |
| CHEBI has role | CHEBI:50247 | antidote |
| FDA EPC | N0000175723 | Cholinesterase Inhibitor |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
Related Drugs by ATC class:
V04CX Other diagnostic agents 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Reversal of neuromuscular blockade | indication | 241703000 | |
| Curare Overdose | indication | ||
| Neuromuscular Block due to Nondepolarizing Drug | indication | ||
| Diagnostic Test for Myasthenia Gravis | indication | ||
| Brain damage | contraindication | 2470005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Myocardial dysfunction | contraindication | 233928007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Drowsy | contraindication | 271782001 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.87 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Enzyme | INHIBITOR | Ki | 8.79 | CHEMBL | CHEMBL | |||
| Acetylcholinesterase | Enzyme | Ki | 6.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019741 | VUID |
| N0000147833 | NUI |
| D00994 | KEGG_DRUG |
| 116-38-1 | SECONDARY_CAS_RN |
| 4017810 | VANDF |
| 4019741 | VANDF |
| C0013615 | UMLSCUI |
| CHEBI:251408 | CHEBI |
| CHEMBL1104 | ChEMBL_ID |
| DB01010 | DRUGBANK_ID |
| CHEMBL1128 | ChEMBL_ID |
| D004491 | MESH_DESCRIPTOR_UI |
| 3202 | PUBCHEM_CID |
| 9073 | IUPHAR_LIGAND_ID |
| 70FP3JLY7N | UNII |
| 3752 | RXNORM |
| 41678 | MMSL |
| 4653 | MMSL |
| d00220 | MMSL |
| 001708 | NDDF |
| 004688 | NDDF |
| 11504003 | SNOMEDCT_US |
| 373342004 | SNOMEDCT_US |
| 46913003 | SNOMEDCT_US |
| EDR | PDB_CHEM_ID |
| 187 | INN_ID |
| 70FP3JLY7N | INXIGHT DRUGS |
Pharmaceutical products:
None